ERBB2 and breast cancer: Patients with Luminal A-/B-like and HER2+/ER+ BC had the longest BMSS (Table 4) with a median of 28 months (6–64) and 34 months (7–62) respectively, whilst patients with HER2+/ER− and TNBC had BMSS of 11 months (0–46) and eight months (0–46) respectively (p = 0.0851).